Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

New oncology compound BIBW 2992 demonstrates potential as a next generation
treatment for non-small cell lung cancer and head-and-neck cancer


News provided by

Boehringer Ingelheim

Jun 03, 2010, 13:49 ET

Share this article

Share toX

Share this article

Share toX

BURLINGTON, ON, June 3 /CNW/ - Boehringer Ingelheim will present promising new data on non-small cell lung cancer as well as head-and-neck cancer for its leading investigational compound BIBW 2992* at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 4-8, 2010.

New data on BIBW 2992 reaffirms its significant anti-tumour activity in non-small-cell lung cancer (NSCLC) patients with EGFR mutations. The data from the LUX-Lung 2 trial shows that(1):

    
    -   The majority of patients (61 per cent) with common EGFR mutations
        showed tumour shrinkage (measured as partial response) when treated
        with BIBW 2992 as assessed by independent review.
    -   Patients with common mutations taking BIBW 2992 have a long time to
        progression (median of approximately 14 months) and a long survival
        (median of 2 years).
    

"The results seen with BIBW 2992 are promising, and could one day offer patients and doctors a new option to treat non-small cell lung cancer," says Dr. Vera Hirsh, Chair, Lung Cancer Committee, McGill University. "Unlike other treatments in its class, BIBW 2992 works differently by irreversibly binding to EGFR and HER2 receptors and may be effective against tumour growth mechanisms that aren't targeted by first generation, reversible EGFR therapy. BIBW 2992 is part of an exciting new trend in personalized medicine, where treatment is individualized based on each patient's tumour characteristics."

In another study, BIBW 2992 was shown to shrink tumours in 22 per cent of patients with head-and-neck cancer (measured as partial response), compared to 13 per cent of those receiving cetuximab(2).

BIBW 2992 is a next generation small molecule targeting the epidermal growth factor receptor (EGFR/HER1) and human epidermal receptor 2 (HER2) receptor tyrosine kinase.

The LUX-Lung Trial Program

The leading pivotal phase III trial, called LUX-Lung 1, is investigating BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with erlotinib or gefitinib. The results of this trial are expected soon.

LUX-Lung 2 is a Phase II trial evaluating BIBW 2992 in NSCLC patients with EGFR mutations, either treatment naïve or after first line chemotherapy. LUX-Lung 2 is part of the comprehensive LUX-Lung clinical trial program.

In two further ongoing global phase III trials, LUX-Lung 3 and LUX-Lung 6, the efficacy and safety of BIBW 2992 is compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations in different geographical regions.

Another trial, LUX-Lung 5, is a global phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized phase III trial investigating whether patients who initially benefit from treatment with BIBW 2992 alone may further benefit from BIBW 2992 beyond progression when given in combination with chemotherapy.

Currently, this clinical trial programme comprises more than ten trials conducted across the globe.

Additional data being presented at ASCO

Apart from BIBW 2992, Boehringer Ingelheim's late stage oncology portfolio includes BIBF 1120*, also development for the treatment of patients in two different indications, advanced NSCLC and ovarian cancer.

Additional phase I and phase II data will be presented at ASCO for BIBW 2992 in glioma and head and neck cancer and for BIBF 1120 in colorectal cancer. (2),(3),(4)

BIBF 1120 is a novel triple angiokinase inhibitor that acts on three growth factors simultaneously: vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) - all crucially involved in the formation of blood vessels.

Both BIBW 2992 and BIBF 1120 are investigational compounds and are not approved in Canada.

About lung cancer in Canada(5)

According to the Canadian Cancer Society, this year, an estimated 24,200 Canadians will be diagnosed with lung cancer and 20,600 will die of it. On average, 465 Canadians will be diagnosed with lung cancer every week and on average, 395 Canadians will die. Lung cancer remains the leading cause of cancer death for both men and women in Canada.

About Head and Neck Cancer

Head and neck cancer can occur in over 30 different places in any of the tissues or organs in the head and neck(6), including in and around the mouth, and it is the sixth most frequently occurring cancer worldwide(7). Most head and neck cancers are squamous cell carcinomas(8), over 90 per cent of which express EGFR(9), which is critical for tumour growth(10). In Canada, 3,400 people will be diagnosed with oral cancer this year alone and 1,150 will die as a result11. Furthermore, 1,150 Canadians will be diagnosed with cancer of the larynx, and 500 will die of the disease(11).

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world's leading cancer centres, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including various solid tumours and haematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. BIBW 2992 is currently in phase III clinical development in NSCLC, and was granted Fast Track designation for a third/fourth line treatment indication in NSCLC by the US Food & Drug Administration. In addition, the LUME-Lung phase III clinical trial program, which is investigating BIBF 1120 in combination with standard second-line chemotherapy treatments for patients with advanced NSCLC, is ongoing. In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing inhibitors of polo-like kinase 1 (Plk-1), a protein that is involved in the processes of cell division. These molecules are in the earlier stages of clinical development.

About Boehringer Ingelheim (Canada) Ltd.

The Boehringer Ingelheim group is one of the world's 15 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and 41,500 employees.

Founded in 1885, the family-owned company is committed to researching and developing novel products of high therapeutic value for human and veterinary medicine. In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 and the Research and Development Centre located in Laval, Québec, Canada since 1988. Boehringer Ingelheim (Canada) Ltd. is home to more than 700 employees including 160 scientists across the country.

* BIBW 2992 and BIBF 1120 are investigational compounds; their safety and efficacy have not yet been fully established. Market Authorization has not been obtained in Canada

For more information please visit www.boehringer-ingelheim.ca.

    
    References

    1.   Chih-Hsin Yang et al. A Phase II study of BIBW 2992 in patients with
         adenocarcinoma of the lunch and activating EGFR mutations (LUX-Lung
         2). Poster presentation at The American Society of Clinical Oncology
         (ASCO) annual meeting, Chicago. June 2010.
         MacMillan Cancer Support.
    2.   Tanguy Y. Seiwert et al. BIBW 2992 versus cetuximab in patients with
         metastatic or recurrent head and neck cancer (SCCHN) after failure
         of platinum-containing therapy with a cross-over period for
         progressing patients: Preliminary results of a randomized, open-
         label Phase II study. Oral presentation at The American Society of
         Clinical Oncology (ASCO) annual meeting, Chicago. June 2010.
    3.   Reardon, A. David et al. Phase I/II study of BIBW 2992 with or
         without daily temozolomide in the treatment of patients with
         recurrent malignant glioma. General poster presentation at The
         American Society of Clinical Oncology (ASCIO) annual meeting,
         Chicago. June 2010.
    4.   Prenen, H et al. A phase I dose escalation study of BIBF 1120
         combined with FOLFOX in metastic colorectal cancer (mCRC) patients
         (pts). Accepted for publication.
    5.   Canadian Cancer Society. Lung Cancer Statistics.
http://www.cancer.ca/Ontario/About%20cancer/Cancer%20statistics/Stats%20at%20a%20glance/Lung%20cancer.aspx?sc_lang=en&r=1
(Accessed May 21, 2010)
    6.   MacMillan Cancer Support.
http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Headneck/Aboutheadneckcancers/Headneckcancers.aspx.
Last accessed 7 May 2010
    7.   Hunter KD et al. Profiling early head and neck cancer. Nat Rev
         Cancer. 2005 Feb; 5 (2): 127-35
    8.   Viviana P. Lutzky. Biomarkers for Cancers of the Head and Neck.
         Clinical Medicine: Ear, Nose and Throat 2008:1
    9.   Grandis, J.R. and Tweardy, D.J. Elevated levels of transforming
         growth factor alpha and epidermal growth factor receptor messenger
         RNA are early markers of carcinogenesis in head and neck cancer.
         Cancer Res., 1993. 53:3579-84.
    10.  Normanno N et al. The ErbB receptors and their ligands in cancer: an
         overview. Current Drug Targets.2005. May;6(3):243-47.
    11.  Canadian Cancer Society Steering Committee: Canadian Cancer
         Statistics 2010. Toronto: Canadian Cancer Society, 2010.

    *  BIBW 2992 and BIBF 1120 are investigational compounds; their safety
         and efficacy have not yet been fully established. Market
         Authorization has not been obtained in Canada.
    *  BIBW 2992 is an investigational compound; its safety and efficacy
         has not yet been fully established. Market Authorization has not
         been obtained in Canada.
    

For further information: Jeanelle Frampton, Environics Communications, (416) 969-2670, [email protected]

Modal title

Organization Profile

Boehringer Ingelheim

    Also from this source

  • Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.